Cargando…
Targeting the P53 Protein for Cancer Therapies: The Translational Impact of P53 Research
It is only recently that drugs targeting K-RAS and Tp53 missense mutations have been developed, and along with the allele specific nature of some of these drugs comes the possibility of combining them with the immunologic therapies for cancers. It has taken about 40 years since their discoveries to...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Association for Cancer Research
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852246/ https://www.ncbi.nlm.nih.gov/pubmed/35110395 http://dx.doi.org/10.1158/0008-5472.CAN-21-2709 |